We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Volex Plc | LSE:VLX | London | Ordinary Share | GB0009390070 | ORD 25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.50 | 0.44% | 339.50 | 337.00 | 339.50 | 340.00 | 334.00 | 339.00 | 83,739 | 11:15:16 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Components, Nec | 722.8M | 36.8M | 0.2031 | 16.67 | 613.21M |
Date | Subject | Author | Discuss |
---|---|---|---|
01/9/2022 09:06 | Sad but true. | steeplejack | |
31/8/2022 19:08 | I agree, can't find many reasons to buy anything at the moment... | johndoe23 | |
31/8/2022 17:50 | I wouldn't trust nat to tell me the time in a room full of clocks. Corrupt and bent as an arabs dagger. | insideryou | |
31/8/2022 12:19 | Excellent link. Thankyou. | pcok | |
31/8/2022 08:10 | thought conclusion positive | ali47fish | |
31/8/2022 07:53 | Downing assets investment letter, contain risk analysis for VLX, worth a read - www.downing.co.uk/as | owenski | |
31/8/2022 07:50 | Scrip dividend | hoodedcrow | |
31/8/2022 07:19 | nat buys 314,230 Ordinary Shares of 25 pence each at a price of 297.60 pence per Ordinary Share. | ali47fish | |
27/8/2022 09:54 | expected response to Jeff Powell's speech at Jackson Hole. | mfhmfh | |
27/8/2022 09:33 | Yep, I've gotta learn to top-slice But this is a chance to grab more at these levels. Over time, it's only going to go back up to 320p and beyond. And then the extra ones bought here will just bring bigger profits. | dougmachin | |
27/8/2022 09:16 | Very disappointing to be back at this level, not surprised though! | johndoe23 | |
22/8/2022 12:23 | Topped up today. Looking forward to the next leg (up) in the story. As usual Nat hints at targeted aquisitions so maybe that will be the first development. | pcok | |
20/8/2022 08:53 | https://www.mailplus | ijamlon | |
19/8/2022 14:00 | Volex issued an AGM trading statement today. Volex's performance in the first quarter has been strong, in line with management's expectations and the new, five-year growth plan. Revenues grew organically by 4.9%, the Group is maintaining higher inventory levels than last year in order to support the timely delivery of complex products to customers. All segments - Electric Vehicles, Consumer Electricals, Medical and Complex Industrial Technology - are seeing solid demand with revenues ahead of last year. The Board expects to deliver full year underlying operating profit in line with current market expectations, around $62.8m, or roughly 50% up on FY22. Net profit and EPS should be commensurately strong. Valuation is average with forward PE ratio of 13.3x roughly mid-range for the Machinery, Equipment & Components sector. Profitability ratios and the balance sheet are solid. There is a lot to like here and the share price appears to have pushed higher out of its 12-month correction. BUY... ...from WealthOracle | km18 | |
19/8/2022 10:47 | Also remember we are talking about USD profit growth for a GBP denominated share. Every $ of profit is worth 15% more in £ terms than it was a year ago. | ijamlon | |
19/8/2022 10:24 | Don't forget potential acquisitions to boost numbers. From today: 'Integration of the acquisitions made during FY2022 is progressing well and Volex continues to develop a strong acquisition pipeline.' | mfhmfh | |
19/8/2022 09:32 | Cannacord comment:Solid AGM trading update with Q1 revenues up c5% y/y against backdrop of positive demand and a challenging supply chain. Utilisation levels are high and inventory build is helping to ensure supply. Demand remains robust across all verticals, including Consumer Electronics where revenues continue to grow. Already expects FY23E operating profit (consensus $62.8m) will be in line with expectations. Trades on CY22E EV/EBITDA 10x and P/E of 14x, which is a c.20% discount to the sector average. DY 1.2%. Looks good value with potential for upside risk to earnings as the year progresses. | ijamlon | |
19/8/2022 09:24 | It's a good update, no doubt about it. This time last year the underlying 2022 profit guidance was $50mln, and the share price was well over £4 flying to £5. A year later, in an unfavourable environment, we've got $62-64mln underlying profit guidance and we're barely at £3. They have consistently delivered impressive growth and shareholder value. For now the market doesn't care. Give it time. | ijamlon | |
19/8/2022 08:47 | I was hoping for more than 4.9% growth but better than nought I suppose, | wskill | |
19/8/2022 08:17 | I have written to them thanking them for once again specifying their understanding of current market expectations | cerrito | |
19/8/2022 07:48 | All divisions doing well. No slowdown in "Medical' - something there was a concern about after Phillips reported something similar earlier ths year from what I can remember. | mfhmfh | |
19/8/2022 07:26 | Nice statement, also pleased they quote what expectations are, often that info is hard to find as a PI. | dr biotech | |
19/8/2022 07:12 | RNS begins AGM Statement ' Strong start to FY2023 and continued progress across the business | togglebrush | |
19/8/2022 07:03 | Solid update. | pcok |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions